Status:
COMPLETED
Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity
Lead Sponsor:
Ain Shams University
Conditions:
Cisplatin Nephrotoxicity
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Cisplatin is a major anti-neoplastic drug used for the treatment of solid tumors. Its chief dose limiting side effect is nephrotoxicity. Twenty percent of patients receiving high-dose cisplatin underg...
Eligibility Criteria
Inclusion
- Cancer patients to receive cisplatin based chemotherapy protocol.
- Adult patients from 18 to 65 years.
Exclusion
- Existing renal impairment ( Creatinine clearance \<30 ml/minute)
- Severe hepatic impairment (Child Pugh score C).
- Hypersensitivity to sulfonamides.
- Patients with chronic non-congestive angle closure glaucoma.
- Hypersensitivity to sulphur compounds, N-acetylcysteine or any component of the formulation.
Key Trial Info
Start Date :
November 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2016
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT02760901
Start Date
November 1 2013
End Date
October 1 2016
Last Update
January 24 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.